No Data
Beijing Bohui Innovation Biotechnology Group (300318.SZ): The microfluidic chip used in the company's in vitro diagnostic test reagents is developed and manufactured by the company.
Gelonghui October 31st | Beijing Bohui Innovation Biotechnology Group (300318.SZ) stated on the investor interaction platform that the microfluidic chip used in the company's in vitro diagnostic test reagents is developed and manufactured by the company, mainly used as a liquid reagent carrier. It achieves the directional flow of liquid reagents in the chip through the pump valve driven by the instrument's gas path module, completing the sample extraction, PCR amplification, DNA reverse hybridization, and other detection processes. The microfluidic chip is used in conjunction with the company's detection analyzers to automate the detection of molecular diagnostic reagents.
Bohui Innovation: 2024 Third Quarter Report
beijing bohui innovation biotechnology group (300318.SZ) released net income for the first three quarters, with a net income of 23.7177 million yuan, an increase of 67.77%.
beijing bohui innovation biotechnology group (300318.SZ) released the third quarter report of 2024, the company's revenue for the first three quarters was 6...
Beijing Bohui Innovation Biotechnology Group (300318.SZ): net income for the first three quarters was 23.7177 million yuan, a year-on-year increase of 67.77%.
Beijing Bohui Innovation Biotechnology Group (300318.SZ) announced its third quarter report for 2024 on October 29. The company achieved revenue of 0.646 billion yuan in the first three quarters of the year, a year-on-year decrease of 19.85%; net income attributable to shareholders of the listed company was 23.7177 million yuan, a year-on-year increase of 67.77%; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 15.6564 million yuan, a year-on-year increase of 29.24%; basic earnings per share were 0.0290 yuan.
Beijing Bohui Innovation Biotechnology Group (300318.SZ): The controlling subsidiary terminated the relevant freeze-dried human rabies vaccine (serum-free Vero cell) project cooperation agreement and drug clinical trials.
Gelonghui September 24th | Beijing Bohui Innovation Biotechnology Group (300318.SZ) announced that its holding subsidiary Bohui Biopharmaceutical Co., Ltd. (formerly known as Ch Env Tech&Bio Pharmaceutical Co., Ltd., hereinafter referred to as "Langfang Bohui") and Chengdu Baoaote Biotechnology Co., Ltd. (hereinafter referred to as "Baoaote") signed a "Project Cooperation Contract" in January 2020, jointly submitted the application for clinical trials of the lyophilized human rabies vaccine (serum-free Vero cells) which Baoaote had completed the preclinical research work for. In July 2020, this vaccine obtained the "Drug Clinical Trial Batch" issued by the National Medical Products Administration.
Beijing Bohui Innovation Biotechnology Group (300318.SZ): Daguang Plasma Station obtained a single plasma license.
On September 11th, Bohui Innovation (300318.SZ) announced that its subsidiary, Bohui Biopharmaceutical (Hebei) Co., Ltd., obtained the Single Plasma Collection License issued by the Health Commission of Yunnan Province. The Da Guan Plasma Station, a subsidiary of Bohui Biopharmaceutical, has been approved and registered, and is now allowed to operate.
No Data
No Data